| Document |
Document Title |
|
WO/2001/042199A1 |
An amidinophenylpyruvic acid derivative represented by the following formula, its analogs and pharmaceutically acceptable salts thereof which have an excellent effect of inhibiting activated blood coagulation factor VII.
|
|
WO2001030749B1 |
The present invention relates to novel compounds, pharmaceutical compositions containing the same as well as a method for treatment of parasitic disorders, wherein said compounds are administered. The present compounds are especially wel...
|
|
WO/2001/032717A2 |
Initiator systems of the invention comprise a complexed initiator comprising a complex of an amidine complexing agent and an initiator; and a decomplexer. The initiator systems are useful for initiating polymerization of at least one mon...
|
|
WO/2001/032611A1 |
The present invention relates to compounds of formula (I), in which A, L, Y and k have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds. They exhibit a strong antithro...
|
|
WO/2001/030148A1 |
This invention relates to novel substituted succinic acid metallo-$g(b)-lactamase inhibitors which are useful potentiators of $g(b)-lactam antibiotics. Accordingly, the present invention provides a method of treating bacterial infections...
|
|
WO/2001/028979A2 |
Disclosed are compounds of formula (I), (II) or (III) which are useful for inhibiting neuraminidases from disease-causing microorganisms, especially, influenza neuraminidase. Also disclosed are compositions and methods for preventing and...
|
|
WO/2001/025188A1 |
The present invention relates to novel carbamates, ureas, and pharmaceutically acceptable salts thereof; compositions comprising the carbamate, urea, or a pharmaceutically acceptable salt thereof; and methods for treating or preventing c...
|
|
WO/2001/025486A1 |
The present invention relates to methods of screening for compounds that bind RNA molecules. In particular, the methods of the invention comprise screening a library of test compounds, each of which is attached to a solid support, with a...
|
|
WO/2001/023348A1 |
The invention relates to stabilized guanidine thiocyanate that contains 5 to 5000 ppm, based on the weight of the guanidine thiocyanate, of thiourea and/or N-acetylcysteine. Due to its excellent light and temperature stability and the lo...
|
|
WO/2001/021582A1 |
The invention relates to compounds of the formula (I), wherein X, R?1¿, R?2¿, R?3¿, R?4¿ and R?5¿ have the meaning indicated in claim 1. The inventive compounds represent inhibitors of the subtype 3 sodium/proton exchanger (NHE-3).
|
|
WO/2001/017977A1 |
The invention relates to novel 1,3,5-triazine derivatives represented by general formula (I) wherein R?1¿, R?2¿, R?3¿, R?4¿, m, n and R?5¿ are defined as described in the specification, and multiple processes and intermediates for t...
|
|
WO/2001/017948A1 |
Derivatives of active ingredients with creatine and ornithine are disclosed having enhanced nutritional and/or therapeutic effects which favourably lend themselves to the preparation of orally administrable solid compositions.
|
|
WO/2001/014324A1 |
The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC 3.4.21.31) of the aryl guanidine type.
|
|
WO/2001/014323A1 |
The invention relates to a method for producing 1-methyl-3-nitroguanidine, comprising the following steps: a) reacting chlorine cyanide or bromine cyanide with methylamine in the presence of an inert organic solvent at temperatures of -3...
|
|
WO/2001/012634A1 |
A compound of formula (I) wherein X is aluminium, gallium or indium; each Y, which may be the same or different, is nitrogen or phosphorus; R?1¿ and R?2¿, which may be the same or different, are hydrogen, halogen or alkyl; and R?3¿ to...
|
|
WO/2001/010835A1 |
Selected compounds of formula (I) are antibacterial agents: formula (I) wherein R¿2? represents a substituted or unsubstituted C¿1?-C¿6? alkyl, cycloalkyl (C¿1?-C¿6? alkyl)- or aryl (C¿1?-C¿6? alkyl)- group, and A represents a gro...
|
|
WO/2001/010849A2 |
The invention relates to new substituted arylalkylamino-1,3,5-triazines of formula (I), wherein n, R?1¿, R?2¿, R?3¿, R?4¿, R?5¿,R?6¿ and R?7¿ have the meaning given in the description, to a method and intermediates for the product...
|
|
WO/2001/010841A2 |
The invention relates to compounds of formula (I) wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, m and n have the meaning given in Claim 1, and to their physiologically acceptable salts and solvates, which can be used as integrin inhibitors,...
|
|
WO/2001/009096A2 |
Compounds of formula (I), are useful in treating diseases prevented by or ameliorated with potassium channel openers. Also disclosed are potassium channel opening compositions and a method of opening potassium channels in a mammal.
|
|
WO/2001/005753A1 |
Diacylhydrazine derivatives of general formula (I) wherein X, Y, Z, R?1¿, R?2¿ and R?3¿ have the meanings cited in Claim 1, and the physiologically acceptable salts or solvates thereof, which are integrin inhibitors and can be used to...
|
|
WO/2001/005752A1 |
The invention concerns a method for making aminoguanidine bicarbonate from an aqueous solution of cyanamide and an aqueous solution of hydrazine hydrate in the presence of CO¿2?. The invention is characterised in that it consists in pro...
|
|
WO/2001/004128A1 |
A chelate comprised of creatine bonded to an essential mineral selected from the group consisting of Mg, Ca, Cu, Zn, Fe, Cr, Co, Mo, Se and Mn to form a heterocyclic ring. Preferably, the metal is Mg, but Ca, Zn, Fe, Cr and Mn are also p...
|
|
WO/2001/000558A1 |
The invention relates to methods for preparing substituted cyclopentene compounds, their intermediates and use as neuraminidase inhibitors.
|
|
WO/2001/000623A1 |
Method of producing compounds of formula (I), wherein R¿1? is hydrogen or C¿1?-C¿4?-alkyl; R¿2? is hydrogen, C¿1?-C¿8?-alkyl, C¿3?-C¿6?-cycloalkyl, or a radical -N(R¿3?)R¿4?; or R¿2? and R¿6? together are -CH¿2?-CH¿2?-S-; R...
|
|
WO/2001/000571A1 |
The invention relates to a process for preparing substituted cyclopentane derivatives represented by formula (I) wherein R?1¿, R?2¿, R?3¿, R?4¿, X and Y are as described in the specification, and pharmaceutically acceptable salts the...
|
|
WO/2001/000206A1 |
Compounds that selectively inhibit the binding of ligands to $g(a)4$g(b)1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by formula (I). As selective inhibi...
|
|
WO/2000/078737A2 |
The invention relates to novel aryloxy ethylamino triazines of general formula (I) in which n, R?1¿, R?2¿, R?3¿ and Z have the meanings cited in the description, whereby compounds N-[4-amino-6- (1-fluoro-1- methyl-ethyl) -1,3,5-triazi...
|
|
WO/2000/076991A1 |
A process is provided for preparing chiral cyclopropane carboxylic acids, preferably of structure (I) which are intermediates used in preparing acyl guanidine sodium/proton exchange (NHE) inhibitors.
|
|
WO/2000/076516A1 |
This invention relates to novel compounds of Formula (I), pharmaceutical compositions and their use in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
WO/2000/076517A1 |
This invention relates to novel compounds of Formula (I), and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
WO/2000/072800A2 |
This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
WO/2000/073258A1 |
Derivatives of active ingredients with amino acids are disclosed having enhanced nutritional and/or therapeutic effects which favourably lend themselves to the preparation of orally administrable solid compositions.
|
|
WO/2000/072840A1 |
This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).
|
|
WO/2000/071160A1 |
Novel medicinal compositions containing anti-Fas antibody which are useful as preventives or remedies for autoimmune diseases or rheumatoid arthritis. More particularly, medicinal compositions containing as the active ingredients antihum...
|
|
WO/2000/069812A1 |
Compounds which are useful as drugs because of not only having a high metalloproteinase inhibitory activity but also being capable of remarkably improving the medicinal activities (for example, oral absorbability) and biological activiti...
|
|
WO/2000/068229A2 |
The present invention relates to S-(-)-optically pure benzoquinolizine carboxylic acid of formula I, and their pharmaceutically acceptable salts, derivatives, pseudopolymorphs, and hydrates, substantially free of their R-(+)-isomers, to ...
|
|
WO/2000/066545A1 |
The invention concerns compounds of general formula (I) wherein: R¿1? represents either a hydrogen atom, or an amino group, or a C¿1?-C¿4? alkyl group, or a C¿1?-C¿6? alkoxycarbonyl group, or a -OH group; R¿2? represents either a C...
|
|
WO/2000/065112A1 |
The process of recovering precious metals from ores containing precious metals, such as gold and silver, from an aqueous ammoniacal thiosulfate leach solution to provide a significant practical and economical process for the recovery of ...
|
|
WO/2000/063189A1 |
The present invention relates to crystalline R- guanidines of (2$i(S)) -2- Ethoxy-3- {4-[2- (10$i(H) -phenoxazin -10-yl) ethoxy]phenyl} propanoate, its preparations and its use as therapeutic agents. More specifically the present inventi...
|
|
WO/2000/063191A1 |
This invention relates to novel polymorphic/pseudopolymorphic forms of arginine salt of 3-[4-[2-(phenoxazin-10-y1)ethoxy]pheny1]-2-ethoxypropanoic acid, having formula (I). The invention also relates to a pharmaceutical composition compr...
|
|
WO/2000/061545A1 |
Compounds of the formula (I) are useful in the treatment of various disorders including, but not limited to, cancer (tumor metathesis, tumorgenesis/tumor growth), angiogenesis (as in cancer, diabetic retinopathy, rheumatoid arthritis), r...
|
|
WO/2000/059875A2 |
Derivatives of aryl and heterocyclic ureido and aryl and heterocyclic carboxamido phenoxy isobutyric acids have been found to inhibit the nonenzymatic glycation of proteins which often results in formation of advanced glycation endproduc...
|
|
WO/2000/048590A1 |
Vascular damaging agents for use in treating diseases involving angiogenesis are provided which are compounds of formula: A-X-B, wherein A is a substituted cis-stilbene moiety, X a linker bond, atom or group and B is a moiety derived fro...
|
|
WO/2000/046187A2 |
The present invention is directed to agmatine and polyamine analogs and their use as drugs, as well as agricultural or environmentally useful agents. As drugs, the analogs decrease cellular polyamine levels, possibly by inducing antizyme...
|
|
WO/2000/044707A1 |
Compounds represented by general formula (1) or prodrugs thereof, or medicinally acceptable salts of both, useful as therapeutic and preventive drugs for diseases due to acceleration of the sodium/proton exchange system wherein R¿1? and...
|
|
WO/2000/042010A1 |
The present invention provides basic ionic contrast agents that have anticoagulant activity. The contrast media incorporate a lysine or arginine group or derivative, and have a free amino or guanidino group. Methods of using the contrast...
|
|
WO/2000/042001A1 |
The invention relates to a pharmaceutical composition comprising as active principle a compound of general formula (I), in which R¿1?, R¿2?, R¿3? and A are as defined in Claim 1. These compositions can be used in the treatment of path...
|
|
WO/2000/040571A1 |
The present invention relates to new compounds for the inhibition of blood clotting proteins, and more particularly, to malonic acid derivatives of formula (I), wherein R(1), R(2), R(3), R(4), R(5), and R(6) have the meanings indicated i...
|
|
WO/2000/040548A1 |
The present invention relates to new compounds for the inhibition of blood clotting proteins, and more particularly, to arylalkanoyl derivatives of formula (I), wherein R(1), R(2), R(3), R(4), R(5), R(6a) and R(6b) have the meanings indi...
|
|
WO/2000/039055A1 |
Novel polyaromatic hydrocarbon quenching reagents of Formula (I), wherein: P is a polyaromatic hydrocarbon of low chemical reactivity which is soluble; Q is one or more quenching reagents, or an acid or base addition salts thereof, that ...
|
